ArticleOpen medicine : a peer-reviewed, independent, open-access journal2011
Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
Article in Open medicine : a peer-reviewed, independent, open-access journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model.Cost effectiveness and resource allocation : C/E · 2024Article
- Healthcare Utilization with Drug Acquisition and Expenses at the National Health Insurance Fund in Sudan.Healthcare (Basel, Switzerland) · 2022Article
- Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.International journal of health policy and management · 2020Article
- Evaluating Price and Availability of Essential Medicines in China: A Mixed Cross-Sectional and Longitudinal Study.Frontiers in pharmacology · 2020Article
- Assessing progressivity and catastrophic effect of out-of-pocket payments for healthcare in Canada: 2010-2015.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals.International journal for equity in health · 2018Article
- Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.Journal of pharmaceutical policy and practice · 2018Review
- Cost-related nonadherence to prescription medications in Canada: a scoping review.Patient preference and adherence · 2018Article
- Out-of-pocket expenditures for pharmaceuticals: lessons from the Austrian household budget survey.The European journal of health economics : HEPAC : health economics in prevention and care · 2017Article
- The financial burden of out of pocket prescription drug expenses in Canada.International journal of health economics and management · 2015Article
- Canadian pharmacare: looking back, looking forward.Healthcare policy = Politiques de sante · 2012Article
- Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.Health policy (Amsterdam, Netherlands) · 2012Article
- Social benefit payments and acute injury among low-income mothers.Open medicine : a peer-reviewed, independent, open-access journal · 2012Article
- The current status of decision-making procedures and quality assurance in Europe: an overview.Medicine, health care, and philosophy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommentaries on the adequacy of insurance coverage for prescription drugs available to Canadians have emphasized differences in the coverage provided by different provincial governments. Less is known about the actual financial burden of prescription drug spending and how this burden varies by province of residence, affluence and source of primary drug coverage.
methodsWe used data from a nationally representative household expenditure survey to analyze the financial burden of prescription drugs. We focused on the drug budget share (defined as the share of the household budget spent on prescription drugs), considering how it varied by province, total household budget and likely primary source of drug insurance coverage (i.e., provincial government plan for senior citizens, social assistance plan or private coverage). We examined both "typical" households (at the median of the distribution of the drug budget share) and households with relatively large shares (in the top 5%). Finally, we estimated the percentage of households with catastrophic drug expenditures (defined as a drug budget share of 10% or more) and the average catastrophic drug expenditures.
resultsSenior, social assistance and general population households accounted for 21.1%, 8.9% and 69.9% of the sample of 14,430 respondents to the 2006 Survey of Household Spending, respectively. The median drug budget share in Canada was 1.1% for senior households (range 0.4% [Ontario] to 3.6% [Saskatchewan]) and 0.1% for both social assistance households and general population households, with little appreciable variation across provinces for these latter 2 categories. The 95th percentile drug budget share in Canada was 7.4% for senior households (range 3.5% [Ontario] to 12.7% [Saskatchewan]), 5.4% for social assistance households (range 2.3% [British Columbia] to 13.0% [Prince Edward Island]) and 2.6% for general population households (range 2.1% [Ontario] to 5.4% [Prince Edward Island]). The interprovincial range of the 95th percentile drug budget share was 10.7 percentage points for social assistance households, 9.2 percentage points for senior households and 3.3 percentage points for general population households.
interpretationFor most households, the financial burden of prescription drug expenditures appeared to be relatively small, with little interprovincial variation. However, a small number of households incurred catastrophic drug costs. These households were concentrated in the groups that traditionally benefit from provincial government drug plans. It is likely that some households did not purchase needed prescription drugs because of the expense, so our estimates of the financial burden of catastrophic prescription drug expenditures therefore represent a lower bound.
Indexed as
Identifiers
22046212PMC3205811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.